Skip to main content
. 2019 Jun 21;116(28):14191–14199. doi: 10.1073/pnas.1908258116

Fig. 5.

Fig. 5.

CpdX, CpdX(eA), CpdX(eB), CpdX-D3, CpdX-D3(eA), or CpdX-D3(eB) alleviate as efficiently as Dex an OVA-induced allergic conjunctivitis. (A) Experimental protocol for generation of an OVA-induced allergic conjunctivitis. (B) Clinical scores (conjunctival hyperemia, lid edema, and tearing) of treated mouse eyes as indicated were evaluated. The data were expressed as mean ± SEM with at least four mice per treatment. (C) Photographs of BALB/c mouse eyes taken 20 min after the last treatment on D23. (D) Immunohistochemistry analyses of eyelid sections from eyes collected on D24 using the eosinophil-specific antibody MBP. (Scale bar, 40 µm.) (E) Immunostaining of corneal flat mounts (from eyes collected on D24) using CD31/PECAM-1 antibody. (Upper) Original photos; (Lower) photos after semiautomatic normalization. (Scale bar, 50 µm.) Data are representative of at least three independent experiments with at least three mice per treatment.